BUSINESS

• Takeda’s Takhzyro Adds Long-Term Efficacy Data on HAE Attack Reduction
  July 14, 2021

• Xarelto Dry Syrup Now Available in Japan: Bayer
  July 13, 2021

• Astellas/Seagen’s ADC Padcev Snags Full Approval, Label Expansion
  July 13, 2021

• Sanofi/GSK COVID-19 Vaccine Enters PIII in Japan
  July 13, 2021

• Teijin Restricting Shipments for Onealfa after Curbs on Edirol
  July 13, 2021

• Towa’s Shipment Control List Expands to 241 Products; 7 Added
  July 13, 2021

• Pfizer R&D, NTT Data to Collaborate with NCC for Efficient Clinical Research
  July 12, 2021

• Enhertu PIII Begins for 2nd Line Use in HER2-Positive Gastric Cancer
  July 12, 2021

• Chugai, Alebund Ink Option and License Pact for Hyperphosphatemia Drug
  July 12, 2021

• Otsuka Files Auto-Injector Version of Migraine Drug Ajovy
  July 9, 2021

• 1,600 Vaccine Doses Ruined at Chugai Due to Flawed Temperature Control
  July 9, 2021

• Fueled by Roivant Deal, Sumitomo Dainippon Accelerating DX as It Looks Beyond Latuda LOE
  July 9, 2021

• FDA Updates Aduhelm Label to Only Cover MCI, Mild Alzheimer’s
  July 9, 2021

• KM Biologics Expects PIII Launch for COVID-19 Vaccine This Autumn: President
  July 8, 2021

• Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
  July 8, 2021

• Bristol Myers Kicks Off COVID-19 Inoculation Program, Eliminates Cost Burden on Employees
  July 8, 2021

• Tecentriq Filed in Japan as Adjuvant Therapy for NSCLC: Chugai
  July 8, 2021

• Bayer’s Vitrakvi Now Available in Japan for NTRK-Positive Solid Tumors
  July 8, 2021

• Japan Ethical Drug Sales Up 6.8% in May: Crecon
  July 8, 2021

• 34 Japan Pharma Execs Earn 100 Million Yen or More in FY2020, Top 3 at Takeda
  July 7, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 232
• 233
• 234
• 235
• 236
• 237
• 238
• 239
• 240
• …
• Next ›
• 最終 »